Docoh
Loading...

LPCN Lipocine

News

From Benzinga Pro
5 Penny Stocks Insiders Are Buying
19 Nov 21
News, Penny Stocks, Small Cap, Insider Trades, Pre-Market Outlook, Markets, Trading Ideas
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
LPCN: Third Quarter Update
11 Nov 21
Penny Stocks
By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT
Lipocine Q3 EPS $(0.03) Up From $(0.07) YoY
10 Nov 21
Earnings, News
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.03) per share. This is a 57.14 percent increase over losses of $(0.07) per share from the same period last year.
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
8 Nov 21
Biotech, Earnings, News, Penny Stocks, Small Cap, IPOs, Top Stories, General
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week.
Lipocine Announces FDA Grants Fast Track Designation To LPCN 1144 For Treatment Of Non-Cirrhotic NASH
4 Nov 21
News, FDA
Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track
12 Health Care Stocks Moving In Tuesday's After-Market Session
19 Oct 21
Movers
Gainers
18 Stocks Moving in Tuesday's Pre-Market Session
19 Oct 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) rose 26.1% to $2.03 in pre-market trading after surging 18% on Monday. Kaival Brands Innovations recently announced plans to launch distribution of its products in the U.K.
Lipocine, Antares Ink Licensing Pact For Testosterone Replacement Therapy In US
18 Oct 21
Biotech, News, Penny Stocks, Health Care, Contracts, Small Cap, General
Lipocine and Antares Pharma Enter Into a Licensing Agreement to Commercialize TLANDO, Lipocine to Receive $11M Upfront and Up to $170M in the Future
18 Oct 21
News
Under the terms of Agreement Lipocine to receive: Up to $21.0 million in licensing fees, including $11.0 million payable immediately and $10.0 million to be paid in the future subject to
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
8 Oct 21
Biotech, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7)
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
7 Oct 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6)
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
6 Oct 21
Biotech, News, Penny Stocks, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5)
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
28 Sep 21
Pre-Market Outlook, Markets, Movers
Lipocine Announces FDA Affirmation Of Class 1 NDA Resubmission For TLANDO
28 Sep 21
News, FDA
Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the U.S. Food and Drug Administration ("FDA") has affirmed the resubmission